Swedish Orphan (Germany) Performance
| B6E Stock | EUR 26.48 0.04 0.15% |
The entity has a beta of -0.28, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Swedish Orphan are expected to decrease at a much lower rate. During the bear market, Swedish Orphan is likely to outperform the market. At this point, Swedish Orphan Biovitrum has a negative expected return of -0.0701%. Please make sure to validate Swedish Orphan's standard deviation, jensen alpha, and the relationship between the coefficient of variation and information ratio , to decide if Swedish Orphan Biovitrum performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Swedish Orphan Biovitrum has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Swedish Orphan is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 404 M | |
| Total Cashflows From Investing Activities | -367 M |
Swedish |
Swedish Orphan Relative Risk vs. Return Landscape
If you would invest 2,822 in Swedish Orphan Biovitrum on September 23, 2024 and sell it today you would lose (174.00) from holding Swedish Orphan Biovitrum or give up 6.17% of portfolio value over 90 days. Swedish Orphan Biovitrum is currently producing negative expected returns and takes up 2.2812% volatility of returns over 90 trading days. Put another way, 20% of traded stocks are less volatile than Swedish, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Swedish Orphan Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Swedish Orphan's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Swedish Orphan Biovitrum, and traders can use it to determine the average amount a Swedish Orphan's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0307
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | B6E |
Estimated Market Risk
| 2.28 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Swedish Orphan is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Swedish Orphan by adding Swedish Orphan to a well-diversified portfolio.
Swedish Orphan Fundamentals Growth
Swedish Stock prices reflect investors' perceptions of the future prospects and financial health of Swedish Orphan, and Swedish Orphan fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Swedish Stock performance.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 | |||
| Profit Margin | 0.14 % | |||
| Current Valuation | 6.67 B | |||
| Shares Outstanding | 295.99 M | |||
| Price To Earning | 18.28 X | |||
| Price To Book | 2.47 X | |||
| Price To Sales | 3.66 X | |||
| Revenue | 15.53 B | |||
| EBITDA | 5.72 B | |||
| Cash And Equivalents | 280.15 M | |||
| Cash Per Share | 1.04 X | |||
| Total Debt | 8.78 B | |||
| Debt To Equity | 39.80 % | |||
| Book Value Per Share | 3.55 X | |||
| Cash Flow From Operations | 5.47 B | |||
| Earnings Per Share | 0.93 X | |||
| Total Asset | 48.66 B | |||
About Swedish Orphan Performance
By analyzing Swedish Orphan's fundamental ratios, stakeholders can gain valuable insights into Swedish Orphan's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Swedish Orphan has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Swedish Orphan has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. SWEDISH ORPHAN is traded on Frankfurt Stock Exchange in Germany.Things to note about Swedish Orphan Biovitrum performance evaluation
Checking the ongoing alerts about Swedish Orphan for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Swedish Orphan Biovitrum help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Swedish Orphan generated a negative expected return over the last 90 days | |
| Swedish Orphan Biovitrum has accumulated 8.78 B in total debt with debt to equity ratio (D/E) of 39.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Swedish Orphan Biovitrum has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Swedish Orphan until it has trouble settling it off, either with new capital or with free cash flow. So, Swedish Orphan's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Swedish Orphan Biovitrum sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Swedish to invest in growth at high rates of return. When we think about Swedish Orphan's use of debt, we should always consider it together with cash and equity. | |
| About 70.0% of Swedish Orphan shares are held by institutions such as insurance companies |
- Analyzing Swedish Orphan's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Swedish Orphan's stock is overvalued or undervalued compared to its peers.
- Examining Swedish Orphan's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Swedish Orphan's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Swedish Orphan's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Swedish Orphan's stock. These opinions can provide insight into Swedish Orphan's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Swedish Stock analysis
When running Swedish Orphan's price analysis, check to measure Swedish Orphan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Swedish Orphan is operating at the current time. Most of Swedish Orphan's value examination focuses on studying past and present price action to predict the probability of Swedish Orphan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Swedish Orphan's price. Additionally, you may evaluate how the addition of Swedish Orphan to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |